Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29971820 | 1.00 | GAA (0.45) | GAAMAPTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL1576898 | 1.00 | GAA (0.45) | GAAMAPTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL12693914 | 1.00 | GAA (0.45) | GAAMAPTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL4014542 | 0.83 | GAA (0.44) | GAAMAPTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL14191690 | 0.83 | GAA (0.44) | GAAMAPTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL4014545 | 0.83 | GAA (0.44) | GAAMAPTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL14191688 | 0.82 | CYP3A4 (0.49) | GAAMAPTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL5491257 | 0.81 | LMNA (0.42) | GAAMAPTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL1192238 | 0.81 | ALDH1A1 (0.44) | GAAMAPTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL1822157 | 0.81 | LMNA (0.42) | GAAMAPTALDH1A1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245351-A1 | PROCESS FOR THE PREPARATION OF LAPATINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | NATCO PHARMA LIMITED (IN) | 2012-09-27 | — | — | US | disclosed |
| EP-1981876-B1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LTD (GB) | 2011-05-04 | — | — | EP | disclosed |
| WO-2011039759-A1 | A NEW PROCESS FOR THE PREPARATION OF LAPATINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | NATCO PHARMA LIMITED (IN) | 2011-04-07 | — | — | WO | disclosed |
| US-20100158863-A1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
| EP-1844004-B1 | QUINAZOLINE DERIVATES AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LTD (GB) | 2009-06-24 | — | — | EP | disclosed |
| EP-1991533-A1 | CHEMICAL COMPOUNDS | Arrow Therapeutics Limited (GB) | 2008-11-19 | — | — | EP | disclosed |
| US-20080267914-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| WO-2008056149-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ARROW THERAPEUTICS LIMITED (GB) | 2008-05-15 | — | — | WO | disclosed |
| US-20080114008-A1 | Quinazoline Derivatives as Antiviral Agents | ARROW THERAPEUTICS LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| EP-1844004-A1 | QUINAZOLINE DERIVATES AS ANTIVIRAL AGENTS | Arrow Therapeutics Limited (GB) | 2007-10-17 | — | — | EP | disclosed |
| WO-2007042782-A1 | CHEMICAL COMPOUNDS | ARROW THERAPEUTICS LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
| WO-2006079833-A1 | QUINAZOLINE DERIVATIVES AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LIMITED (GB) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158863-A1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | SLC28A1, TPMT, ACE | GAA 348/4885MAPT 2681/4885ALDH1A1 443/4885 |
| US-20120245351-A1 | PROCESS FOR THE PREPARATION OF LAPATINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | ABL1, ERBB2, EGFR | GAA 3214/4885MAPT 1668/4885ALDH1A1 4115/4885 |
| US-20080267914-A1 | Chemical Compounds | RNASEL, ZC3HAV1L, RNASEH1 | GAA 1317/4885MAPT 4645/4885ALDH1A1 294/4885 |
| US-20080114008-A1 | Quinazoline Derivatives as Antiviral Agents | IFNAR1, C5, EIF2AK2 | GAA 2208/4885MAPT 4840/4885ALDH1A1 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.